Discovery of a rare GKAP1-NTRK2 fusion in a pediatric low-grade glioma, leading to targeted treatment with TRK-inhibitor larotrectinib

Medicine and Dentistry

• Neoplasm 100%
• Ganglioglioma 100%
• Pediatrics 100%
• Targeted Therapy 100%
• Larotrectinib 100%
• Protein Tyrosine Kinase 66%
• Tumor Progression 66%
• Chimeric Protein 66%
• Clinical Examination 33%
• Mediator 33%
• Optic Chiasm 33%
• Hypothalamus 33%
• Transient Transfection 33%
• Sanger Sequencing 33%
• Amino Acid 33%
• Ribosome Protein 33%
• Cell Signaling Pathway 33%
• Copy Number Variation 33%
• Clinical Trial 33%
• Quality of Life 33%
• Reverse Transcription Polymerase Chain Reaction 33%
• Exon 33%
• Mitogen-Activated Protein Kinase 33%
• Pilocytic Astrocytoma 33%

Biochemistry, Genetics and Molecular Biology

• Tyrosine Kinase 100%
• Receptor Tyrosine Kinase 100%
• Tumor Progression 100%
• Chimeric Protein 100%
• Wild Type 50%
• Copy-Number Variation 50%
• Clinical Trial 50%
• Amino Acids 50%
• Reverse Transcription Polymerase Chain Reaction 50%
• Ribosomal Protein 50%
• Exon 50%
• Mediator 50%
• Transient Transfection 50%
• Mitogen-Activated Protein Kinase 50%
• Dideoxynucleotide Sequencing 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Larotrectinib 100%
• Neoplasm 100%
• Protein Tyrosine Kinase 66%
• Tumor Growth 66%
• Chimeric Protein 66%
• Chemotherapy 33%
• Clinical Trial 33%
• Amino Acid 33%
• Ribosome Protein 33%
• Pilocytic Astrocytoma 33%